Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43,360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study.
Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, Qiu S, Pan S, Zheng Y, Cai J, Chen X, Qu S, Lin L, Huang J, Wu H, Lu Y, Wang W, Hu C, He X, Yu Z, Liu X, Xie B, Liu A, Hu G, Jing S, Zhang Q, Guo R, Li Q, Hong J, Jin F, Meng J, Shi J, Wang P, Cui J, Yang K, Zhang X, Li X, Shen L, He Y, Zhai L, Sun X, Ge J, Qing Y, Zong D. Shi Y, et al. Among authors: sun x. Lancet Reg Health West Pac. 2022 Oct 10;31:100617. doi: 10.1016/j.lanwpc.2022.100617. eCollection 2023 Feb. Lancet Reg Health West Pac. 2022. PMID: 36879786 Free PMC article.
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Zhang Q, Hu J, Zhou H, Xiong Y, Liu P. Shi Y, et al. Among authors: sun x. Lancet Haematol. 2019 Jan;6(1):e12-e19. doi: 10.1016/S2352-3026(18)30192-3. Lancet Haematol. 2019. PMID: 30612710 Clinical Trial.
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Xiong Y, Zhou H, Du X, Wang X, Peng B. Shi Y, et al. Among authors: sun x. EBioMedicine. 2020 Apr;54:102731. doi: 10.1016/j.ebiom.2020.102731. EBioMedicine. 2020. PMID: 32304999 Free PMC article. Clinical Trial.
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201).
Song Y, Zhou K, Jin C, Qian Z, Hou M, Fan L, Li F, Ding K, Zhou H, Li X, Chen B, Sun X, Song X, Jiang M, Zhang Q, Liu L, Yu G, Hu Y, Zhao Z, Liu L, Xue H, Luo J, He B, Jin X, Zhao M, Li B, Xia Y, Zhu J. Song Y, et al. Among authors: sun x. Front Oncol. 2022 Jul 7;12:925236. doi: 10.3389/fonc.2022.925236. eCollection 2022. Front Oncol. 2022. PMID: 35875118 Free PMC article.
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X, Qiu L, Yang J, Yang Y, Wang Z, Hu J, Wang H, Su H, Jin Z, Qian W, Jin C, Zhang M, Yu D, Liu L, Chen G, Li Y, Sun T, Jin J, Bao H, Du X, Zhou H, Fu G, Shi Y. Qin Y, et al. Among authors: sun t, sun x. BMC Cancer. 2024 Jan 24;24(1):124. doi: 10.1186/s12885-024-11876-9. BMC Cancer. 2024. PMID: 38267866 Free PMC article. Clinical Trial.
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, Zhao W, Zhang H, Sun X, Yang H, Zhang X, Jin J, Jin Z, Li Z, Qiu L, Dong M, Huang X, Luo Y, Wang X, Wang X, Wu J, Xu J, Yi P, Zhou J, He H, Liu L, Shen J, Tang X, Wang J, Yang J, Zeng Q, Zhang Z, Cai Z, Chen X, Ding K, Hou M, Huang H, Li X, Liang R, Liu Q, Song Y, Su H, Gao Y, Liu L, Luo J, Su L, Sun Z, Tan H, Wang H, Wang J, Wang S, Zhang H, Zhang X, Zhou D, Bai O, Wu G, Zhang L, Zhang Y. Shi Y, et al. Among authors: sun z, sun x. J Hematol Oncol. 2017 Mar 15;10(1):69. doi: 10.1186/s13045-017-0439-6. J Hematol Oncol. 2017. PMID: 28298231 Free PMC article.
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Zhang Y, Liu P, Cai J, Jing H, Zou L, Huang H, Wu Y, Li W, Zhong L, Jin X, Ye X, Feng R, Zhang H, Zhang L, Lin L, Sun X, Tian Y, Xia Z, Li Z, Huang H, Xia Y, Cai Q. Zhang Y, et al. Among authors: sun x. Cancer Med. 2022 Nov;11(22):4134-4145. doi: 10.1002/cam4.4765. Epub 2022 Apr 19. Cancer Med. 2022. PMID: 35438258 Free PMC article.
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Wang T, Sun X, Qiu L, Su H, Cao J, Li Z, Song Y, Zhang L, Li D, Wu H, Zhang W, Li J, Zhou K, Zhou H, Yang Y, Li Z, Cen H, Cai Z, Zhang Z, Fu W, Jin J, Li F, Wu W, Gu X, Zhu W, Liu L, Li Z, Yi S, Bao H, Xu Z, Qiu L. Wang T, et al. Among authors: sun x. Clin Cancer Res. 2023 Apr 14;29(8):1440-1449. doi: 10.1158/1078-0432.CCR-22-2939. Clin Cancer Res. 2023. PMID: 36735519 Free PMC article. Clinical Trial.
43,360 results
You have reached the last available page of results. Please see the User Guide for more information.